5 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#SideEffects #Table ... #DecisionAid #Orals ... #DM2 #Diabetes ... #Endocrinology # ... Pharmacology #Management
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... Summary Mechanisms ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... Summary Mechanisms ... Most effective oral ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
to treat Type 2 Diabetes ... There is an ORAL ... GLP1 #Agonists #Pharmacology ... #Dosing #Diabetes ... #DM2 #Endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
Rybelsus (oral semaglutide ... ) - First Oral GLP ... first (& only) oral ... Oral semaglutide ... #Rybelsus #oral